Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.


Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
04 2020
Historique:
received: 21 08 2019
revised: 28 10 2019
accepted: 20 11 2019
pubmed: 8 12 2019
medline: 7 10 2021
entrez: 8 12 2019
Statut: ppublish

Résumé

Georgia, with a high prevalence of HCV infection, launched the world's first national hepatitis C elimination program in April 2015. A key strategy is the identification, treatment, and cure of the estimated 150,000 HCV-infected people living in the country. We report on progress and key challenges from Georgia's experience. We constructed a care cascade by analyzing linked data from the national hepatitis C screening registry and treatment databases during 2015-2018. We assessed the impact of reflex hepatitis C core antigen (HCVcAg) testing on rates of viremia testing and treatment initiation (i.e. linkage to care). As of December 31, 2018, 1,101,530 adults (39.6% of the adult population) were screened for HCV antibody, of whom 98,430 (8.9%) tested positive. Of the individuals who tested positive, 78,484 (79.7%) received viremia testing, of whom 66,916 (85.3%) tested positive for active HCV infection. A total of 52,576 people with active HCV infection initiated treatment and 48,879 completed their course of treatment. Of the 35,035 who were tested for cure (i.e., sustained virologic response [SVR]), 34,513 (98.5%) achieved SVR. Reflex HCVcAg testing, implemented in March 2018, increased rates of monthly viremia testing by 97.5% among those who screened positive for anti-HCV, however, rates of treatment initiation decreased by 60.7% among diagnosed viremic patients. Over one-third of people living with HCV in Georgia have been detected and linked to care and treatment, however, identification and linkage to care of the remaining individuals with HCV infection is challenging. Novel interventions, such as reflex testing with HCVcAg, can improve rates of viremia testing, but may result in unintended consequences, such as decreased rates of treatment initiation. Linked data systems allow for regular review of the care cascade, allowing for identification of deficiencies and development of corrective actions. This report describes progress in Georgia's hepatitis C elimination program and highlights efforts to promote hepatitis C virus screening and treatment initiation on a national scale. Georgia has made progress towards eliminating hepatitis C, treating over 50,000 people, approximately one-third of the number infected, and achieving cure for 98.5% of those tested. However, identifying infected individuals and linking them to care remains challenging. Novel approaches to increase diagnostic testing can have unintended consequences further down the care cascade.

Sections du résumé

BACKGROUND & AIMS
Georgia, with a high prevalence of HCV infection, launched the world's first national hepatitis C elimination program in April 2015. A key strategy is the identification, treatment, and cure of the estimated 150,000 HCV-infected people living in the country. We report on progress and key challenges from Georgia's experience.
METHODS
We constructed a care cascade by analyzing linked data from the national hepatitis C screening registry and treatment databases during 2015-2018. We assessed the impact of reflex hepatitis C core antigen (HCVcAg) testing on rates of viremia testing and treatment initiation (i.e. linkage to care).
RESULTS
As of December 31, 2018, 1,101,530 adults (39.6% of the adult population) were screened for HCV antibody, of whom 98,430 (8.9%) tested positive. Of the individuals who tested positive, 78,484 (79.7%) received viremia testing, of whom 66,916 (85.3%) tested positive for active HCV infection. A total of 52,576 people with active HCV infection initiated treatment and 48,879 completed their course of treatment. Of the 35,035 who were tested for cure (i.e., sustained virologic response [SVR]), 34,513 (98.5%) achieved SVR. Reflex HCVcAg testing, implemented in March 2018, increased rates of monthly viremia testing by 97.5% among those who screened positive for anti-HCV, however, rates of treatment initiation decreased by 60.7% among diagnosed viremic patients.
CONCLUSIONS
Over one-third of people living with HCV in Georgia have been detected and linked to care and treatment, however, identification and linkage to care of the remaining individuals with HCV infection is challenging. Novel interventions, such as reflex testing with HCVcAg, can improve rates of viremia testing, but may result in unintended consequences, such as decreased rates of treatment initiation. Linked data systems allow for regular review of the care cascade, allowing for identification of deficiencies and development of corrective actions.
LAY SUMMARY
This report describes progress in Georgia's hepatitis C elimination program and highlights efforts to promote hepatitis C virus screening and treatment initiation on a national scale. Georgia has made progress towards eliminating hepatitis C, treating over 50,000 people, approximately one-third of the number infected, and achieving cure for 98.5% of those tested. However, identifying infected individuals and linking them to care remains challenging. Novel approaches to increase diagnostic testing can have unintended consequences further down the care cascade.

Identifiants

pubmed: 31811882
pii: S0168-8278(19)30710-X
doi: 10.1016/j.jhep.2019.11.019
pmc: PMC7418146
mid: NIHMS1616602
pii:
doi:

Substances chimiques

Antiviral Agents 0
Hepatitis C Antibodies 0
Hepatitis C Antigens 0
RNA, Viral 0
Viral Core Proteins 0
nucleocapsid protein, Hepatitis C virus 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

680-687

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Published by Elsevier B.V.

Références

Aliment Pharmacol Ther. 2019 May;49(9):1223-1229
pubmed: 30908706
Lancet Glob Health. 2020 Feb;8(2):e244-e253
pubmed: 31864917
MMWR Morb Mortal Wkly Rep. 2015 Jul 24;64(28):753-7
pubmed: 26203628
J Hepatol. 2019 Oct;71(4):645-647
pubmed: 31356831
MMWR Morb Mortal Wkly Rep. 2019 Jul 26;68(29):637-641
pubmed: 31344021
MMWR Morb Mortal Wkly Rep. 2017 Jul 28;66(29):773-776
pubmed: 28749925
Lancet Gastroenterol Hepatol. 2018 Oct;3(10):665
pubmed: 30215356
Ann Intern Med. 2017 Sep 5;167(5):311-318
pubmed: 28785771
Nat Rev Gastroenterol Hepatol. 2017 Jul 26;14(8):447-448
pubmed: 28743936
MMWR Morb Mortal Wkly Rep. 2016 Oct 21;65(41):1132-1135
pubmed: 27764081
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184
pubmed: 30647010
Ann Intern Med. 2016 Sep 6;165(5):345-55
pubmed: 27322622
Clin Infect Dis. 2019 Sep 29;:
pubmed: 31563938
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126
pubmed: 30552056
BMC Public Health. 2019 May 10;19(Suppl 3):480
pubmed: 32326913
J Virus Erad. 2019 Jan 1;5(1):60-66
pubmed: 30800429

Auteurs

Francisco Averhoff (F)

Centers for Disease Control and Prevention, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention, Atlanta, Georgia, USA. Electronic address: fma0@cdc.gov.

Shaun Shadaker (S)

Centers for Disease Control and Prevention, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention, Atlanta, Georgia, USA.

Amiran Gamkrelidze (A)

National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.

Tatia Kuchuloria (T)

TEPHINET independent contractor for Georgia Hepatitis C Elimination Program, Atlanta, Georgia, USA.

Lia Gvinjilia (L)

TEPHINET independent contractor for Georgia Hepatitis C Elimination Program, Atlanta, Georgia, USA.

Vladimer Getia (V)

National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia.

David Sergeenko (D)

Ministry of IDPs from the Occupied Territories, Labour, Health, and Social Affairs of Georgia, Tbilisi, Georgia.

Maia Butsashvili (M)

Health Research Union, Tbilisi, Georgia.

Tengiz Tsertsvadze (T)

Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.

Lali Sharvadze (L)

Hepatology clinic HEPA, Tbilisi, Georgia.

Jaba Zarkua (J)

Hepatology and Gastroenterology Department, Medical Center Mrcheveli, Tbilisi, Georgia.

Beth Skaggs (B)

Division of Global Health Protection, Center for Global Health, South Caucasus Regional Office, Tbilisi, Georgia.

Muazzam Nasrullah (M)

Centers for Disease Control and Prevention, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH